BMY
Bristol-Myers Squibb Company
Stock
$61.15−0.31 (−0.50%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $12.8B | $14.2B | $15.2B | $13.9B | $13.1B | $16.2B | $14.1B | $8.2B | $7.1B | $5.3B | $3.1B | $2.1B | $3.1B | $3.5B | $6.9B | $4.8B | $4.5B | $4.1B | $3.7B | $3.2B |
| Capital expenditures | $1.3B | $1.3B | $1.2B | $1.2B | $1.1B | $973M | $753M | $836M | $951M | $1.1B | $1.2B | $820M | $526M | $537M | $548M | $367M | $424M | $730M | $941M | $843M |
| Free cash flow | $11.4B | $12.8B | $13.9B | $12.7B | $11.9B | $15.2B | $13.3B | $7.4B | $6.1B | $4.2B | $1.8B | $1.3B | $2.6B | $3.0B | $6.4B | $4.5B | $4.1B | $3.3B | $2.8B | $2.3B |
| Stock-based compensation | $553M | $553M | $507M | $518M | $457M | $583M | $779M | $441M | $221M | $199M | $205M | $235M | $213M | $191M | $154M | $161M | $193M | $183M | $181M | $133M |
| Buybacks | — | $0 | $0 | $5.2B | $8.0B | $6.3B | $1.5B | $7.3B | $320M | $2.5B | $231M | — | — | $433M | $2.4B | $1.2B | $576M | — | — | — |
| Dividends paid | $5.1B | $5.0B | $4.9B | $4.7B | $4.6B | $4.4B | $4.1B | $2.7B | $2.6B | $2.6B | $2.5B | $2.5B | $2.4B | $2.3B | $2.3B | $2.3B | $2.2B | $2.5B | $2.5B | $2.2B |
| Dividends per share | $2.51 | $2.49 | $2.42 | $2.31 | $2.19 | $2.01 | $1.84 | $1.68 | $1.61 | $1.57 | $1.53 | $1.49 | $1.45 | $1.41 | $1.37 | $1.33 | $1.29 | $1.25 | $1.24 | $1.15 |
| Free cash flow margin | 23.3% | 26.7% | 28.9% | 28.1% | 25.9% | 32.8% | 31.3% | 28.2% | 27.1% | 20.3% | 9.5% | 7.8% | 16.5% | 18.4% | 36.3% | 21.1% | 20.9% | 17.7% | 15.6% | 14.8% |